High risk HPV testing following treatment for cervical intraepithelial neoplasia
MetadataShow full item record
This item's downloads: 307 (view details)
Cited 3 times in Scopus (view citations)
Molloy, M., Comer, R., Rogers, P., Dowling, M., Meskell, P., Asbury, K., & O’Leary, M. (2016). High risk HPV testing following treatment for cervical intraepithelial neoplasia. Irish Journal of Medical Science (1971 -), 185(4), 895-900. doi: 10.1007/s11845-015-1392-4
To determine the results of combined cytology and high-risk human papilloma virus (HR HPV) tests at 6 and 18 months postcolposcopy treatment at one Irish colposcopy centre.All women who attended the centre's colposcopy smear clinic for a co-test 6 months (initial test) posttreatment were included in the audit (n = 251).The results revealed negative HR HPV for 79 % (n = 198) of women tested 6 months after treatment and positive results for 21 % (n = 53). HR HPV testing was more sensitive than cytology and led to early detection of residual disease. No women with negative HR HPV had high-grade cytology.HR HPV is more sensitive than cytology for detection of persistent CIN. However, 19 women with positive HR HPV had normal colposcopy with no persistent CIN detected. A national cost-benefit analysis is recommended to determine the value of the second co-test.